Uncontrolled trial of Rituximab treatment on refractory or steroid dependent nephrotic syndrome in adult.

Uncontrolled trial of Rituximab treatment on refractory or steroid dependent nephrotic syndrome in adult. - Uncontrolled trial of Rituximab treatment on refractory or steroid dependent nephrotic syndrome in adult.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014355

Enrollment

Registered

2014-07-01

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory or steroid dependent nephrotic syndrome

Interventions

rituximab 375mg/m2 single-dose 1 time/6months 24 months follow up

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Refractory nephrotic syndrome patients. Steroid dependent nephrotic syndrome patients. Patients gave written informed consent for participation in the study

Exclusion criteria

Exclusion criteria: Positive serology for hepatitis B, Cardiac failure, Lung dysfunction, Bone marrow dysfunction, Pregnant subjects or subjects who do not agree with contraception during the study period

Design outcomes

Primary

Measure	Time frame
Remission rate Relapse rate The cumulative dose of prednisolone and immunosuppressive drug	—

Secondary

Measure	Time frame
The adverse effect of prednisolone. The adverse effect of immunosuppressive drug The adverse effect of rituximab	—

Countries

Japan

Contacts

Public ContactYusuke Watanabe

Saitama Medical University Department of Nephrology

yusuke_w@saitama-med.ac.jp049-276-1612

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026